ZYNE(Delisted)
Zynerba PharmaceuticalsยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ZYNE
Zynerba Pharmaceuticals, Inc.
The leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders
80 W. Lancaster Avenue, Suite 300, Devon, PA 19333
--
Zynerba Pharmaceuticals, Inc. was incorporated in Delaware on January 31, 2007 as AllTranz, Inc., and changed its name to Zynerba Pharmaceuticals, Inc., in August 2014. The Company is a ten-year-old specialty pharmaceutical company dedicated to the development and marketing of proprietary next-generation synthetic cannabinoid treatments for transdermal drug delivery. Its management team has extensive experience, and has successively developed patch and gel transdermal drug delivery products, which have been approved by the regulatory authorities, which is a successful history of commercialization. The company is evaluating two patent-protected product candidates, ZYN002 and ZYN001.
Company Financials
EPS
ZYNE has released its 2023 Q2 earnings. EPS was reported at -0.21, versus the expected -0.2, missing expectations. The chart below visualizes how ZYNE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
